Search

Your search keyword '"Grohé, Christian"' showing total 569 results

Search Constraints

Start Over You searched for: Author "Grohé, Christian" Remove constraint Author: "Grohé, Christian"
569 results on '"Grohé, Christian"'

Search Results

1. Evolutionary trajectories of small cell lung cancer under therapy

4. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

5. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

6. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

7. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

10. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

12. TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading

14. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

18. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

19. Corrigendum to “First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations” [Eur J Cancer 199 (2024) 113556]

21. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry

22. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment – A multicenter analysis

24. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

28. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

29. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy

30. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study

31. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis

32. TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading

33. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

34. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

35. Medikamentöse Therapie der pulmonalarteriellen Hypertonie mit Komorbiditäten – Welche Phänotypen gibt es, was gibt es zu beachten?

37. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

39. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

40. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

42. Genetic and geographic influence on phenotypic variation in European sarcoidosis patients

43. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

44. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients with Resected Stage IB–IIIA EGFR-Mutated Non-Small Cell Lung Cancer: Updated Analysis from the Phase 3 ADAURA Trial

45. Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122)

46. Toll-like receptor 4 deficiency: Smaller infarcts, but nogain in function

47. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function.

50. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment

Catalog

Books, media, physical & digital resources